アブストラクト
Japanese
| Title | 便中カルプロテクチン検査の臨床における有用性について |
|---|---|
| Subtitle | 新技術特集 |
| Authors | 千葉明子 |
| Authors (kana) | |
| Organization | サーモフィッシャーダイアグノスティックス株式会社 マーケティング本部自己免疫診断薬部 |
| Journal | 生物試料分析 |
| Volume | 43 |
| Number | 3 |
| Page | 193-199 |
| Year/Month | 2020 / |
| Article | 報告 |
| Publisher | 生物試料分析科学会 |
| Abstract | 「I. はじめに」炎症性腸疾患(IBD)の患者数は増加しており, 本邦における2015年の研究班による疫学調査では, 潰瘍性大腸炎(UC)の推定患者数がおよそ22万人, クローン病(CD)の推定患者数がおよそ7万人と報告されている. 近年では, IBDの治療薬や治療目標は進歩しており, そのためIBD患者の病態を的確に把握するバイオマーカーが求められてきた. 便中カルプロテクチン検査は, 本邦では2017年に保険適用となった比較的新しい検査であるが, 欧米では本邦に先行して臨床応用が進んでいる. 現在ではInternational organization for the study of inflammatory bowel disease (IOIBD)の報告やEuropean Crohn's and Colitis Organization(ECCO)のガイドラインでもIBDにおける当検査の有用性について示されている. |
| Practice | 基礎医学・関連科学 |
| Keywords | Calprotectin, Inflammatory bowel disease, Ulcerative colitis, Crohn's disease, Biomarker, Mucosal healing |
English
| Title | Clinical usefulness of fecal calprotectin |
|---|---|
| Subtitle | Topics |
| Authors | Sayako Chiba |
| Authors (kana) | |
| Organization | Autoimmunity Diagnostics, Marketing Department, Thermo Fisher Diagnostics |
| Journal | Journal of Analytical Bio-Science |
| Volume | 43 |
| Number | 3 |
| Page | 193-199 |
| Year/Month | 2020 / |
| Article | Report |
| Publisher | The Society of Analytical Bio-Science |
| Abstract | [Summary] Recently, number of Inflammatory bowel disease (IBD) patients, which includes Ulcerative colitis (UC) and Crohn's disease (CD), has been increasing, and many kinds of drugs and diagnostics of biomarkers for IBD are developed. Fecal calprotectin (FC) measurement is an intestinal inflammation biomarker specific to IBD with non-invasive and low-cost. FC measurement has been widely used in Europe and the United States. In Japan, the clinical utilities of FC measurement for IBD has reported and applied to clinical practice, recently. In this paper, we show the clinical usefulness of FC measurement with Fluorescence Enzyme Immunoassay (FEIA) method. |
| Practice | Basic medicine |
| Keywords | Calprotectin, Inflammatory bowel disease, Ulcerative colitis, Crohn's disease, Biomarker, Mucosal healing |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) 炎症性腸疾患(IBD)診療ガイドライン2016.日本消化器病学会,南江堂,東京(2016).
- 2) 西脇祐司 他: 潰瘍性大腸炎およびクローン病の右病者数推計に関する全国疫学調査.難治性疾患の継続的な疫学データの収集・解析に関する研究(H26-難治等(難)-一般-089)総合研究報告書(2017).
- 3) Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L: A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol, 114: 874-883, 2019.
- 4) Maaser C et al: ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis, 13: 144-164, 2019.
- 5) 平成30年度 衛生行政報告例 特定医療費(指定難病)受給者証所持者数.
残りの19件を表示する
- 6) 炎症性腸疾患(第2版)病因解明と診断・治療の最新知見.株式会社 日本臨床社, 7-70, 東京(2018).
- 7) Neurath MF: Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol, 20: 970-979, 2019.
- 8) Caruso R, Lo BC, Nunez G: Host-microbiota interactions in inflammatory bowel disease. Nat Rev Immunol, Jan 31. doi: 10.1038/s41577-019-0268-7. 2020.
- 9) Peyrin-Biroulet L et al: Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 110: 1324-38, 2015.
- 10) IBD Research 2016 Vol.10 No.4, 株式会社 先端医学社, 6-17, 東京(2016).
- 11) Roseth AG, Schmidt PN, Fagerhol MK: correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol, 34: 50-54, 1999.
- 12) Vermeire S, Van Assche G, Rutgeerts P: Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut, 55: 426-431, 2006.
- 13) Ton H, Brandsnes, Dale S, Holtlund J, Skuibina E, Schjonsby H, Johne B: Improved assay for fecal calprotectin. Clin Chim Acta, 292: 41-54, 2000.
- 14) Roseth AG, Fagerhol MK, Aadland E, Schjonsby H: Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol, 27: 793-798, 1992.
- 15) Kubo M et al: Differences between risk factors among irritable bowel syndrome subtypes in Japanese adults. Neurogastroenterol Motil, 23: 249-254, 2011.
- 16) Vavricka SR et al: Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis, 18: 496-505, 2012.
- 17) Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I: Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology, 123: 450-460, 2002.
- 18) van Rheenen PF, Van de Vijver E, Fidler V: Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ, 15: 341:c3369, 2010.
- 19) D'Haens G et al: Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis, 18: 2218-2224, 2012.
- 20) Yamamoto T, Shimoyama T, Matsumoto K: Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis. Aliment Pharmacol Ther, 42: 549-558, 2015.
- 21) Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I: Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology, 119: 15-22, 2000.
- 22) Guardiola J et al: Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol, 12: 1865-1870, 2014.
- 23) Lasson A, Ohman L, Stotzer PO, Isaksson S, Uberbacher O, Ung KA, Strid H: Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. United European Gastroenterol J, 3: 72-79, 2015.
- 24) Rugtveit J, Fagerhol MK: Age-Dependent Variations in Fecal Calprotectin Concentrations in Children. J Pediatr Gastroenterol Nutr, 34: 323-324, 2002.
